

Henning Gädeke, Chair of the Global Health EDCTP3 Joint Undertaking Governing Board

c/o Executive Director Michael Makanga, Global Health EDCTP3 Joint Undertaking

Global Health EDCTP3 Joint Undertaking

56 – 60 Avenue de la Toison d'Or

1060 Brussels

Belgium

August 29, 2025

Letter of endorsement

Dear Sir/Madam,

On behalf of University of California, San Francisco (UCSF), 1855 Folsom Street, Ste 425 San Francisco, CA 94103 (EIN# 94-6036493) and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

UCSF and the Infectious Diseases Research Collaboration (IDRC): Prof. Moses Kamya and Dr. Joaniter Nankabirwa (MU, IDRC) have collaborated on research with Dr. Grant Dorsey (UCSF) since 2010. Prof. Kamya is the current Executive Director of the Infectious Diseases Research Collaboration (IDRC) which has a memorandum of understanding in place with Makerere University (MU) for this organization to operate as the legal management center for Makerere University research and training projects. A memorandum of understanding is in place between UCSF-Makerere University and UCSF-IDRC for scientific collaboration. IDRC is a registered NGO and is recognized as such by the Republic of Uganda. It is located in Nakasero Hill in Kampala, near Mulago Hospital. IDRC will be responsible for personnel management; purchasing equipment and supplies in Uganda; purchasing, insuring, and maintaining research vehicles at local cost and adhering to UCSF and U.S. NIH guidelines; creating and upholding agreements for space for research activities in Uganda; and maintaining and ensuring financial transparency of grants through multiple funding sources including the NIH and EDCTP.

This letter of Endorsement supports our role as Partners in the TACTIC (Final ID:101249134-2) proposal to the HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage call. UCSF is the primary recipient of a U.S. National Institutes of Health grant (U01AI186861, Multiple PI: Dorsey (primary, UCSF), Nankabirwa (M-PI, IDRC)) which support work that will contribute to the achievement of the objectives of the TACTIC proposal. Specifically, this proposal, and our contribution to it, will evaluate a novel approach to reducing malaria transmission while limiting the spread of drug-resistant malaria parasites.

The TACTIC proposal supports harmonized efforts across two cluster randomized clinical trials, one in Uganda and one on Burkina Faso, to evaluate context-specific approaches to malaria chemoprevention targeting school-age children to reduce malaria transmission in the whole community. Harmonized outcome measures of these trials as well as coordinated approaches to measure impacts on drug resistance, education, as well as large-scale economic and societal impact are key deliverables of the approach proposed in TACTIC. Data from two study sites with different

malaria endemicities will be pivotal for decision making at WHO and the coordinated approach will provide key evidence for other global and regional policy makers as well as Ministries of Finance and external funders.

We estimate the total value of this contribution to be EUR 3.97 million. As a Contributing Partner in the TACTIC proposal, UCSF will provide, via NIH grant U01AI186861, funding to IDRC (Uganda) to support the framework for the proposed Uganda trial (WP3b) including trial sponsorship, procurement of antimalarial drugs, support for administration of study drugs, data collection for school-based surveys and costing data required for economic analyses (WP6). We will also provide salary support for IDRC leadership and supervision of these activities (WP1). This support will continue for the duration of the TACTIC proposal.


We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,



Grant Dorsey, MD, PhD
Professor of Medicine
University of California San Francisco



Joaniter Nankabirwa, MChB PhD
Associate Director
Infectious Disease Research Collaboration